A new study on the impact of Cystic Fibrosis carrier status in in vitro fertilization (IVF) procedures and outcomes, entitled “Female cystic fibrosis mutation carriers and assisted reproductive technology: Does carrier status affect reproductive outcomes?“ was recently announced by Celmatix, a New York City-based company…
News
Santa Fe, New Mexico based startup Avisa Pharma Inc. is a clinical stage company established in 2010 to develop and commercialize a new technology invented by Dr. Graham Timmins, Avisa’s Co-founder/Chief Science Officer and a University of New Mexico College of Pharmacy Associate Professor, who was assisted by colleagues from UNM’s School…
Drug discovery company Proteostasis Therapeutics has completed the recruiting process for its Inaugural Cystic Fibrosis Clinical Advisory Board, a new board appointed by the company to act as a strategic resource responsible for the selection of upcoming studies of its compounds for treating cystic fibrosis. The company is dedicated…
A new study on Staphylococcus aureus infection and cystic fibrosis (CF) entitled “Counteracting suppression of CFTR and voltage-gated K+ channels by a bacterial pathogenic factor with the natural product tannic acid“ was published on eLife by Yajamana Ramu, part of Dr. Zhe Lu’s group…
McElhattan, Pennsylvania-based Nutek Disposables is conducting a voluntary product recall on the United States for their baby wipes, due to a report of bacteria in some of the packages, which may be dangerous for cystic fibrosis (CF) patients in particular. The wipes were manufactured under the brand names of Cuties,…
The European Medicines Agency (EMA) recently reviewed products containing the antibiotics colistin or colistimethate sodium (known as polymyxins) and recommended alterations to product sheet information to include safety and the most updated information when applied to treating infections that demonstrated to be resistant to other standard antibiotics. This update…
Vertex Pharmaceuticals‘ Ivacaftor (Kalydeco), a breakthrough medication for the treatment of patients suffering from a specific gene mutation of cystic fibrosis, has been approved to be added to the list of the Pharmaceutical Benefits Scheme (PBS) in Australia, and will become available on December 1st, as announced by Australian…
An Optical Society release notes that while people might typically regard mucus as an “icky bodily secretion best left wrapped in a tissue,” for a group of researchers from the University of North Carolina at Chapel Hill, “snot is an endlessly fascinating subject.” The team has developed a way to use…
A new study on the effect of female hormones in pulmonary exacerbations in cystic fibrosis patients, entitled “Subcutaneous implant with etonogestrel (Implanon®) for catamenial exacerbations in a patient with cystic fibrosis: a case report” and published in the journal BMC Pulmonary Medicine by Dr. Adelaida Lamas,…
Advocates and fundraisers for Cystic Fibrosis continue to develop creative, unique ways to increase awareness of the disease throughout the world and support ongoing clinical research for effective, new therapeutic strategies. Recently, the Cystic Fibrosis Association of New Zealand (CFNZ) joined forces with Ballentynes Fashion Central to organize a fundraising fashion show…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.